News
First-in-human trial of ETX–636 to begin in Q2 2025 in patients with tumors harboring an activating PI3Kα mutation, including breast cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback